Tivozanib

What is Tivozanib?

Tivozanib is an oral, potent, and highly selective vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor. It is primarily used in the treatment of certain types of cancer. Specifically, it is approved for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) who have received two or more prior systemic therapies. Marketed under the brand name Fotivda, Tivozanib represents a crucial advancement in targeted therapy, offering a specific mechanism to combat tumor growth by interfering with the blood supply that fuels cancer cells.

Unlike traditional chemotherapy, which broadly targets rapidly dividing cells, Tivozanib belongs to a class of drugs that precisely targets molecular pathways involved in cancer development and progression. This selectivity often translates to a different side effect profile compared to conventional treatments, making it an important option for patients whose disease has progressed despite prior therapeutic interventions.

How Does it Work?

The mechanism of action of Tivozanib revolves around its ability to inhibit the activity of vascular endothelial growth factor receptors (VEGFRs). These receptors, specifically VEGFR-1, VEGFR-2, and VEGFR-3, play a critical role in angiogenesis, the process by which new blood vessels are formed. In cancer, tumors often hijack this process to develop their own blood supply, which is essential for their growth, survival, and metastasis.

By acting as a tyrosine kinase inhibitor, Tivozanib binds to and blocks the intracellular signaling pathways initiated by VEGFRs. This blockade prevents the activation of these receptors, thereby inhibiting the formation of new blood vessels that would otherwise supply oxygen and nutrients to the tumor. Consequently, Tivozanib starves the tumor, hindering its growth and spread. Its high selectivity for VEGFRs, particularly VEGFR-2, contributes to its efficacy and potentially a more manageable toxicity profile compared to less selective inhibitors.

Medical Uses

The primary medical indication for Tivozanib is the treatment of advanced renal cell carcinoma (RCC). RCC is the most common type of kidney cancer in adults, and advanced forms can be particularly challenging to treat, especially after initial therapies have failed.

• Advanced Renal Cell Carcinoma: Tivozanib is specifically approved for adult patients with relapsed or refractory advanced RCC who have previously received two or more systemic therapies. This includes prior VEGFR-TKI and/or immuno-oncology (IO) based treatments. Its approval is based on clinical trials demonstrating its ability to improve progression-free survival in this challenging patient population.
• Role in Sequential Therapy: Given its specific mechanism and efficacy in previously treated patients, Tivozanib serves as an important option in the sequential treatment strategies for advanced RCC, offering extended disease control where other therapies may no longer be effective.

It is crucial that the decision to use Tivozanib is made by a healthcare professional experienced in cancer treatment, considering the individual patient's medical history, prior treatments, and overall health status.

Dosage

The dosage of Tivozanib must be determined by a healthcare professional and is typically administered orally. Patients should strictly adhere to their doctor's instructions regarding dose and schedule.

• Standard Dosing: The usual recommended dose for adults with advanced renal cell carcinoma is 1.34 mg once daily for 21 consecutive days, followed by a 7-day rest period. This constitutes a 28-day treatment cycle.
• Administration: Tivozanib capsules should be swallowed whole with water, with or without food. It is important to take the medication at approximately the same time each day to maintain consistent drug levels.
• Dose Modifications: Dose adjustments may be necessary based on individual patient tolerance and the occurrence of adverse reactions. This may involve reducing the dose or temporarily interrupting treatment. Patients should never adjust their dose without consulting their physician.
• Missed Dose: If a dose is missed, patients should take it as soon as they remember, unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. Doubling up on doses is not recommended.

Side Effects

Like all medications, Tivozanib can cause side effects, although not everyone experiences them. It is important to discuss any concerns with your doctor or pharmacist.

Common Side Effects:

• Hypertension (High Blood Pressure): This is a very common side effect and often requires monitoring and management with anti-hypertensive medications.
• Fatigue or Asthenia (weakness)
• Diarrhea
• Nausea and vomiting
• Dysphonia (hoarseness)
• Decreased appetite
• Hand-foot syndrome (Palmar-plantar erythrodysesthesia)
• Proteinuria (protein in the urine)
• Hypothyroidism (underactive thyroid)
• Headache

Serious Side Effects:

Patients should seek immediate medical attention if they experience any of the following serious side effects:

• Severe hypertension or hypertensive crisis.
• Arterial thrombotic events (e.g., heart attack, stroke).
• Hemorrhage (bleeding).
• Cardiac dysfunction, including heart failure.
• Gastrointestinal perforation or fistula.
• Hepatotoxicity (liver problems).
• Thyroid dysfunction requiring treatment.

Regular monitoring by a healthcare professional is essential to manage and mitigate potential side effects.

Drug Interactions

Tivozanib can interact with other medications, which may alter its effectiveness or increase the risk of side effects. It is crucial to inform your doctor about all prescription, over-the-counter, and herbal supplements you are taking.

• CYP3A4 Inhibitors and Inducers: Tivozanib is metabolized by the cytochrome P450 enzyme CYP3A4. Co-administration with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir) may increase Tivozanib concentrations, potentially leading to increased side effects. Conversely, strong CYP3A4 inducers (e.g., rifampin, carbamazepine, St. John's Wort) may decrease Tivozanib concentrations, reducing its efficacy.
• P-glycoprotein (P-gp) Inhibitors: Tivozanib is a substrate of P-gp. Co-administration with P-gp inhibitors (e.g., verapamil, amiodarone, cyclosporine) may increase Tivozanib exposure.
• Other Anti-angiogenic Agents: Concurrent use with other drugs that affect angiogenesis may increase the risk of adverse events such as hemorrhage or arterial thrombotic events.
• Warfarin and other Anticoagulants: Caution is advised when co-administering Tivozanib with anticoagulants due to the increased risk of bleeding.

Your doctor will evaluate potential drug interactions and make necessary adjustments to your treatment plan.

FAQ

What is Tivozanib used for?

Tivozanib is used to treat adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) who have received two or more prior systemic therapies.

How is Tivozanib taken?

It is taken orally once daily for 21 consecutive days, followed by a 7-day rest period, completing a 28-day treatment cycle. It can be taken with or without food.

What are the common side effects of Tivozanib?

Common side effects include high blood pressure (hypertension), fatigue, diarrhea, nausea, hoarseness, decreased appetite, hand-foot syndrome, and protein in the urine.

Is Tivozanib a form of chemotherapy?

No, Tivozanib is not traditional chemotherapy. It is a targeted therapy that works by inhibiting specific pathways (VEGFRs) involved in cancer growth and blood vessel formation, rather than broadly targeting rapidly dividing cells.

What is Fotivda?

Fotivda is the brand name under which Tivozanib is marketed for its medical uses.

Products containing Tivozanib are available through trusted online pharmacies. You can browse Tivozanib-based medications at ShipperVIP or Medicenter.

Summary

Tivozanib (Fotivda) represents a significant therapeutic option for patients battling advanced renal cell carcinoma (RCC) who have exhausted other treatment avenues. As a potent and selective VEGFR inhibitor, it precisely targets the blood supply of tumors, effectively hindering their growth and spread. While offering hope for improved progression-free survival, patients receiving Tivozanib must be closely monitored for potential side effects, particularly hypertension and other vascular events. Through careful management and adherence to prescribed dosages, Tivozanib plays a vital role in extending and improving the quality of life for a specific population of cancer patients, underscoring the ongoing advancements in targeted therapy for oncology.